These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26784362)

  • 41. [Acute myelogenous leukemia in elderly].
    Mori M
    Rinsho Ketsueki; 1999 Feb; 40(2):77-80. PubMed ID: 10199195
    [No Abstract]   [Full Text] [Related]  

  • 42. Dose-intensive treatment of acute myelogenous leukemia: improved survival?
    Schiller G
    J Clin Oncol; 1995 Jul; 13(7):1828-30. PubMed ID: 7602375
    [No Abstract]   [Full Text] [Related]  

  • 43. Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased?
    Arlin ZA; Hagenbeek A; Feldman EJ; Andreeff M
    Acta Haematol; 1989; 82(4):175-8. PubMed ID: 2511718
    [No Abstract]   [Full Text] [Related]  

  • 44. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?
    Swords R; Santini V
    Hematology Am Soc Hematol Educ Program; 2012; 2012():74-5. PubMed ID: 23233563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?
    Berman E
    J Clin Oncol; 1995 Jan; 13(1):1-4. PubMed ID: 7799008
    [No Abstract]   [Full Text] [Related]  

  • 46. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
    Ferguson P; Hills RK; Grech A; Betteridge S; Kjeldsen L; Dennis M; Vyas P; Goldstone AH; Milligan D; Clark RE; Russell NH; Craddock C;
    Haematologica; 2016 Nov; 101(11):1351-1358. PubMed ID: 27540133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. G-CSF priming in acute myelogenous leukemia.
    Murashige N; Kami M; Takaue Y
    N Engl J Med; 2003 Nov; 349(21):2071-2; author reply 2071-2. PubMed ID: 14627794
    [No Abstract]   [Full Text] [Related]  

  • 48. Recombinant granulocyte colony-stimulating factor in acute myelogenous leukemia.
    Munck JN; Deacaudin D; Koscielny S
    N Engl J Med; 1995 Oct; 333(17):1155-6. PubMed ID: 7565966
    [No Abstract]   [Full Text] [Related]  

  • 49. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S; Itou S; Shibata A
    Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.
    Mayer RJ
    Semin Oncol; 1987 Dec; 14(4):384-96. PubMed ID: 3321443
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of adult acute leukemia.
    McCauley DL
    Clin Pharm; 1992 Sep; 11(9):767-96. PubMed ID: 1521402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Myelogenous system cells' activity in the bone marrow in children with acute leukemia remission].
    Rybczyńska J; Sikorska-Fic B; Wasik M; Rokicka-Milewska R
    Wiad Lek; 1998; 51 Suppl 4():124-8. PubMed ID: 10731955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Remission maintenance therapy in acute myelogenous leukemia.
    Embury SH; Elias L; Heller PH; Hood CE; Greenberg PL; Schrier SL
    West J Med; 1977 Apr; 126(4):267-72. PubMed ID: 266313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Follow-up 26 years after treatment for acute myelogenous leukemia.
    Clift RA; Thomas ED;
    N Engl J Med; 2004 Dec; 351(23):2456-7. PubMed ID: 15575071
    [No Abstract]   [Full Text] [Related]  

  • 56. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
    Cheson BD; Bennett JM; Kopecky KJ; Büchner T; Willman CL; Estey EH; Schiffer CA; Doehner H; Tallman MS; Lister TA; Lo-Coco F; Willemze R; Biondi A; Hiddemann W; Larson RA; Löwenberg B; Sanz MA; Head DR; Ohno R; Bloomfield CD;
    J Clin Oncol; 2003 Dec; 21(24):4642-9. PubMed ID: 14673054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [History, current status, and future prospects in clinical study of myeloid leukemia].
    Ozawa K
    Nihon Rinsho; 2009 Oct; 67(10):1841-6. PubMed ID: 19860177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
    Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
    Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia.
    Schiller G; Lee M
    Leuk Lymphoma; 1997 Mar; 25(1-2):111-9. PubMed ID: 9130619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.